Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Leonard L. Mazur | Co-Founder, CEO, Chairman & Secretary | 688.75k | -- | 1945 |
| Mr. Myron Z. Holubiak | Co-Founder & Executive Vice Chairman | 652.5k | -- | 1947 |
| Mr. Jaime Bartushak | Chief Business Officer & CFO | 589.03k | -- | 1968 |
| Mr. Gary F. Talarico | Executive Vice President of Operations | -- | -- | 1955 |
| Ms. Ilanit Allen | Vice President of Investor Relations & Corporate Communications | -- | -- | -- |
| Dr. Alan Lader Ph.D. | Senior VP and Head of Clinical Operations & Quality Assurance | -- | -- | -- |
| Dr. Myron S. Czuczman M.D. | Executive VP & Chief Medical Officer | 571.38k | -- | 1960 |
| Mr. Dhananjay G. Wadekar | Senior Vice President of Business Strategy | -- | -- | 1954 |
| Mr. Kelly Creighton Ph.D. | Executive Vice President of Chemistry, Manufacturing & Controls | -- | -- | -- |
| Mr. Nikolas Burlew | Executive Vice President of Quality Assurance | -- | -- | -- |
Citius Pharmaceuticals, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 23
Description
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. The Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido completed. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Corporate Governance
Upcoming Events
May 12, 2025 at 10:59 AM UTC - May 16, 2025 at 12:00 PM UTC
Citius Pharmaceuticals, Inc. Earnings Date